The publisher regrets the omission of the following Acknowledgements, Role of funding source and Conflict of interest information in the original publication. RHMW, KB, GMG, JH, CK, JR, SS and AHY contributed as authors on the manuscript and meet the criteria for authorship as recommended by the International Committee of Medical Journal Editors. They take full responsibility for the scope, direction, content of, and editorial decisions relating to the manuscript, were involved at all stages of manuscript development and have approved the submitted manuscript. The steering committee was initiated and supported by the pharmaceutical company Lundbeck Ltd, through an educational grant. Lundbeck Ltd had no input or influence on content, on the decision to publish, or on the preparation of the manuscript. Medical writing assistance was contracted and compensated by Lundbeck Ltd. The authors received no compensation related to the development of the manuscript. Conflict of interest disclosures. AHY has received payment for lectures and advisory boards from all major pharmaceutical companies with drugs used in affective and related disorders; is the Lead Investigator for the Embolden Study (AstraZeneca), BCI Neuroplasticity Study and Aripiprazole Mania Study; investigator-initiated studies from AstraZeneca, Eli Lilly, Lundbeck and Wyeth; and received grant funding (past and present) from NIMH (USA), CIHR (Canada), NARSAD (USA), Stanley Medical Research Institute (USA), MRC (UK), Wellcome Trust (UK), Royal College of Physicians (Edinburgh, UK), BMA (UK), UBC-VGH Foundation (Canada), WEDC (Canada), CCS Depression Research Fund (Canada), MSFHR (Canada) and NIHR (UK). AHY is funded by the NIHR: the views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. GMG has received payment for consulting/advisory roles from H. Lundbeck, Medscape, MSD, Otsuka, Servier, Sunovion and Takeda; received speaker honoraria from H. Lundbeck, Medscape and Servier; received payment for clinical trials/research grants from Bailey Thomas Charitable Trust, Wellcome Trust and NIHR; has stocks with P1VITAL; and received book royalties from Fast Facts: Bipolar Disorder. GMG is an NIHR senior investigator; the views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. JH has in the past 2 years received paid consultancy from the following companies and organisations: Abbvie, Access to Quality, Amgen, Anavex, AstraZeneca, Avonex, Avraham, Axon, Axovant, Biogen Idec, Boehringer Ingelheim, Bracket, Catenion, CRF Health, DeNDRoN, EnVivo Pharma, Enzymotec, ePharmaSolutions, Eisai, Eli Lilly, Forum Pharma, GfHEu, Heptares, Janssen AI, Johnson & Johnson, Kaasa Health, Kyowa Hakko Kirin, Lundbeck, MedAvante, Merck, MyCognition, Mind Agilis, Neurocog, Neurim, Neurotrack, Novartis, Nutricia, Orion Pharma, Pharmanet/i3, Pfizer, Prana Biotech, PriceSpective, Probiodrug, Prophase, Prostrakan, Regeneron, Reviva, Roche, Sanofi, Servier, Shire, Takeda, TCG, TransTech Pharma, Velacor; has received payment for CME activities from Medscape and Lundbeck; holds options and a patent in Neurotrack and MyCognition, respectively; has received royalties from Oxford University Press and Blackwell Publishers; and has received research funding from Memorabel. CK has received honoraria, grant funding and consultancy payments from pharmaceutical companies including H. Lundbeck and Eli Lilly. RHMW has received speaker fees from AstraZeneca, Bristol Myers-Squibb, Eli Lilly, Ferrer, GlaxoSmithKline, Janssen-Cilag, H. Lundbeck, Merck Sharp & Dohme, Pfizer, Servier, SPIMACO, Sunovian and Wyeth; received consultancy fees from AstraZeneca, Bristol Myers-Squibb, Cyberonics, Eli Lilly, Ferrer, Janssen-Cilag, H. Lundbeck, Merck Sharp & Dohme, MyTomorrow, Servier, Sunovian and Wyeth; and received independent investigator-led research support from AstraZeneca, Eli Lilly and Wyeth. JR has received payment for consultancy/advisory boards/Speaker Bureaus from Alzheimer's Society, Cerestim Ltd, Chase Pharmaceuticals, Edmund de Rothschild, Eli Lilly, H. Lundbeck, Ono, Otsuka, Pfizer, Roche, Servier, Wellcome Trust and Psi-napse, and is a non-executive Director for Cerestim. KB and SS have no conflicts of interest to disclose.